ijms-logo

Journal Browser

Journal Browser

Targeting Stromal Cell Signaling within the Tumor Microenvironment

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Immunology".

Deadline for manuscript submissions: closed (31 March 2023) | Viewed by 7282

Special Issue Editors


E-Mail Website
Guest Editor
College of Pharmacy, Roosevelt University, 1400 N Roosevelt Blvd, Schaumburg, IL 60173, USA
Interests: tumor microenvironment; cell–cell signaling; cell metabolism; hypoxia; oxidative stress; drug repurposing; ovarian cancer; breast cancer
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Cell and Molecular Medicine, Rush Medical College, Rush University Medical Center, Chicago, IL 60612, USA
Interests: molecular pharmacology; drug discovery; gynecologic malignancies; drug repurposing; tumor microenvironment

Special Issue Information

Dear Colleagues,

Advances describing the interactions within cells in the tumor microenvironment (TME) have identified the dependencies of tumor cells on signaling arising from stromal cells within these tissues that are required for tumor development, progression, and resistance to standard therapeutic approaches. Preclinical studies demonstrate that targeting the stromal compartment within the TME may inhibit tumor cell self-renewal, proliferation, invasion, angiogenesis, immune evasion and other mechanisms involved in treatment resistance. There remains, however, an urgent need to further develop our understanding of the contribution of stromal cells to these important processes that are exploited by cancer cells which may define novel interactions that can be targeted using new or repurposed pharmacologic agents. In this Special Issue "Targeting Stromal Cell Signaling within the Tumor Microenvironment", we will highlight new research that elucidates the novel interactions within the TME, which may provide actionable mechanisms to exploit therapeutically, as well as discuss advances in preclinical therapeutic targeting of the TME, which may inform new approaches to improve patient outcomes.

This Special Issue is open to both original research manuscripts and review articles focusing on novel tumor–stromal signaling and advances in the preclinical evaluation of approaches to modulate the tumor microenvironment to improve therapeutic strategies.

Dr. Peter C. Hart
Dr. Michael Bradaric
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • fibroblast
  • adipocyte
  • endothelial cell
  • macrophage
  • t cell
  • nk cell
  • extracellular matrix
  • extracellular vesicles
  • cytokines

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

16 pages, 1347 KiB  
Review
A Cell-Based Systematic Review on the Role of Annexin A1 in Triple-Negative Breast Cancers
by Lishantini Pearanpan, Fariza Juliana Nordin, Ee Ling Siew, Endang Kumolosasi, Ezanee Azlina Mohamad Hanif, Siti Fathiah Masre, Eng Wee Chua, Hong Sheng Cheng and Nor Fadilah Rajab
Int. J. Mol. Sci. 2022, 23(15), 8256; https://doi.org/10.3390/ijms23158256 - 26 Jul 2022
Cited by 6 | Viewed by 3324
Abstract
Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype that is often associated with a poorer prognosis and does not respond to hormonal therapy. Increasing evidence highlights the exploitability of Annexin A1 (AnxA1), a calcium dependent protein, as a precision medicine for [...] Read more.
Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype that is often associated with a poorer prognosis and does not respond to hormonal therapy. Increasing evidence highlights the exploitability of Annexin A1 (AnxA1), a calcium dependent protein, as a precision medicine for TNBC. To systematically summarize the role of AnxA1 and its associated mechanisms in TNBC, we performed data mining using three main databases: PubMed, Scopus, and Ovid/Medline. The papers retrieved were based on two different sets of key words such as “Annexin A1” or “Lipocortin 1” and “Breast cancer” or “TNBC”. A total of 388 articles were identified, with 210 chosen for comprehensive screening and 13 papers that met inclusion criteria were included. Current evidence from cell culture studies showed that AnxA1 expression is correlated with NF-κB, which promotes migration by activating ERK phosphorylation. AnxaA1 also activates TGF-β signaling which upregulates MMP-9 and miR196a expression to enhance epithelial-mesenchymal transition and migratory capacity of TNBC cells. AnxA1 can steer the macrophage polarization toward the M2 phenotype to create a pro-tumor immune environment. Existing research suggests a potential role of AnxA1 in the metastasis and immune landscape of TNBC tumors. Preclinical and clinical experiments are warranted to investigate the feasibility and effectiveness of targeting AnxA1 in TNBC. Full article
(This article belongs to the Special Issue Targeting Stromal Cell Signaling within the Tumor Microenvironment)
Show Figures

Figure 1

20 pages, 1634 KiB  
Review
Notch Signaling in Breast Tumor Microenvironment as Mediator of Drug Resistance
by Adele Chimento, Maria D’Amico, Vincenzo Pezzi and Francesca De Amicis
Int. J. Mol. Sci. 2022, 23(11), 6296; https://doi.org/10.3390/ijms23116296 - 4 Jun 2022
Cited by 19 | Viewed by 3194
Abstract
Notch signaling dysregulation encourages breast cancer progression through different mechanisms such as stem cell maintenance, cell proliferation and migration/invasion. Furthermore, Notch is a crucial driver regulating juxtracrine and paracrine communications between tumor and stroma. The complex interplay between the abnormal Notch pathway orchestrating [...] Read more.
Notch signaling dysregulation encourages breast cancer progression through different mechanisms such as stem cell maintenance, cell proliferation and migration/invasion. Furthermore, Notch is a crucial driver regulating juxtracrine and paracrine communications between tumor and stroma. The complex interplay between the abnormal Notch pathway orchestrating the activation of other signals and cellular heterogeneity contribute towards remodeling of the tumor microenvironment. These changes, together with tumor evolution and treatment pressure, drive breast cancer drug resistance. Preclinical studies have shown that targeting the Notch pathway can prevent or reverse resistance, reducing or eliminating breast cancer stem cells. In the present review, we will summarize the current scientific evidence that highlights the involvement of Notch activation within the breast tumor microenvironment, angiogenesis, extracellular matrix remodeling, and tumor/stroma/immune system interplay and its involvement in mechanisms of therapy resistance. Full article
(This article belongs to the Special Issue Targeting Stromal Cell Signaling within the Tumor Microenvironment)
Show Figures

Figure 1

Back to TopTop